

## STOCK PRICES OF SELECTED BIOTECHNOLOGY SPECIALTY FIRMS

	Price Dec. 15	Price Jan. 15	Percent Change	52 Week Hi-Low	Market Capitalization in \$ millions (stock price × number of shares outstanding)
<b>Companies Emphasizing Recombinant DNA Technology</b>					
Advanced Genetic Sciences	7	9	+29	14 <sup>3</sup> / <sub>4</sub> -6 <sup>1</sup> / <sub>4</sub>	98
*Amgen	6 <sup>3</sup> / <sub>4</sub>	8	+19	18-5 <sup>3</sup> / <sub>4</sub>	81
*Bio Logicals	1 <sup>7</sup> / <sub>8</sub>	1 <sup>3</sup> / <sub>4</sub>	-7	6 <sup>1</sup> / <sub>2</sub> -1 <sup>1</sup> / <sub>2</sub>	10
*Biogen	10 <sup>1</sup> / <sub>4</sub>	12 <sup>7</sup> / <sub>8</sub>	+26	24 <sup>1</sup> / <sub>4</sub> -9 <sup>3</sup> / <sub>4</sub>	238
*Biotech Research Labs	9 <sup>1</sup> / <sub>4</sub>	8 <sup>1</sup> / <sub>4</sub>	-11	21 <sup>1</sup> / <sub>2</sub> -6 <sup>1</sup> / <sub>2</sub>	42
*Biotechnica International	6	8 <sup>1</sup> / <sub>2</sub>	+42	17 <sup>1</sup> / <sub>4</sub> -6	32
Biotechnology General	7	7	0	10-5 <sup>1</sup> / <sub>2</sub>	38
California Biotechnology	12	12 <sup>1</sup> / <sub>2</sub>	+4	14-11 <sup>3</sup> / <sub>4</sub>	60
*Cetus	10 <sup>7</sup> / <sub>8</sub>	12 <sup>7</sup> / <sub>8</sub>	+18	19-10 <sup>1</sup> / <sub>2</sub>	283
Chiron	7 <sup>3</sup> / <sub>4</sub>	8 <sup>1</sup> / <sub>4</sub>	+6	12 <sup>1</sup> / <sub>4</sub> -6	56
*Collaborative Research	8 <sup>1</sup> / <sub>2</sub>	9	+6	15 <sup>1</sup> / <sub>2</sub> -6 <sup>1</sup> / <sub>2</sub>	89
Cooper Biomedical	6 <sup>1</sup> / <sub>2</sub>	7 <sup>3</sup> / <sub>8</sub>	+13	11 <sup>3</sup> / <sub>8</sub> -5 <sup>7</sup> / <sub>8</sub>	131
*Enzo Biochem	25	25 <sup>1</sup> / <sub>4</sub>	+1	34 <sup>1</sup> / <sub>4</sub> -16 <sup>3</sup> / <sub>4</sub>	220
*Genentech	34	38 <sup>3</sup> / <sub>4</sub>	+14	49 <sup>3</sup> / <sub>4</sub> -25 <sup>7</sup> / <sub>8</sub>	550
*Genex	13 <sup>3</sup> / <sub>8</sub>	14 <sup>1</sup> / <sub>4</sub>	+5	23 <sup>1</sup> / <sub>4</sub> -12 <sup>1</sup> / <sub>2</sub>	182
Integrated Genetics	6 <sup>1</sup> / <sub>4</sub>	6	-4	13-4 <sup>3</sup> / <sub>4</sub>	49
*Molecular Genetics	11 <sup>1</sup> / <sub>2</sub>	14	+30	23-10 <sup>7</sup> / <sub>8</sub>	85
<b>Companies Emphasizing Antibody Production Technologies</b>					
*Bio-Response	10 <sup>1</sup> / <sub>8</sub>	13 <sup>7</sup> / <sub>8</sub>	+37	16 <sup>1</sup> / <sub>8</sub> -8	110
*Cambridge BioScience	4	3 <sup>3</sup> / <sub>4</sub>	-6	17 <sup>1</sup> / <sub>4</sub> -3	15
*Centocor	13	15 <sup>3</sup> / <sub>8</sub>	+18	25 <sup>1</sup> / <sub>2</sub> -12	108
*Damon Biotech	9	9 <sup>3</sup> / <sub>4</sub>	+8	17 <sup>3</sup> / <sub>8</sub> -6 <sup>3</sup> / <sub>4</sub>	187
*Genetic Systems	8 <sup>7</sup> / <sub>8</sub>	10 <sup>1</sup> / <sub>8</sub>	+14	17 <sup>3</sup> / <sub>4</sub> -7 <sup>7</sup> / <sub>8</sub>	199
*Hybritech	19 <sup>1</sup> / <sub>4</sub>	22 <sup>1</sup> / <sub>4</sub>	+16	31-18 <sup>3</sup> / <sub>4</sub>	229
*Monoclonal Antibodies	11 <sup>3</sup> / <sub>8</sub>	15	+29	23 <sup>1</sup> / <sub>2</sub> -10 <sup>1</sup> / <sub>2</sub>	36
*Summa Medical	6 <sup>3</sup> / <sub>8</sub>	6 <sup>3</sup> / <sub>8</sub>	0	18 <sup>3</sup> / <sub>8</sub> -5 <sup>7</sup> / <sub>8</sub>	51
<b>Companies Emphasizing Other Products or Biotechnologies</b>					
Applied Biosystems	17	20 <sup>1</sup> / <sub>2</sub>	+21	20 <sup>1</sup> / <sub>2</sub> -13	98
Cell Products	16	15 <sup>1</sup> / <sub>4</sub>	-5	24-7 <sup>3</sup> / <sub>4</sub>	64
*Genetic Engineering Inc.	5 <sup>1</sup> / <sub>2</sub>	5 <sup>1</sup> / <sub>8</sub>	-7	10 <sup>7</sup> / <sub>8</sub> -3 <sup>3</sup> / <sub>4</sub>	12
*Immunex	6 <sup>1</sup> / <sub>2</sub>	8 <sup>3</sup> / <sub>4</sub>	+35	13 <sup>3</sup> / <sub>4</sub> -6	50
*Interferon Sciences	5 <sup>1</sup> / <sub>8</sub>	5	-2	11-4	20
*Ribi Immunochem	7 <sup>1</sup> / <sub>4</sub>	10	+38	16 <sup>1</sup> / <sub>2</sub> -5 <sup>3</sup> / <sub>4</sub>	30
Vega Biotechnologies	4 <sup>3</sup> / <sub>4</sub>	5 <sup>1</sup> / <sub>4</sub>	+11	11 <sup>1</sup> / <sub>2</sub> -3 <sup>1</sup> / <sub>4</sub>	14

The BIO/TECHNOLOGY Index of Specialty Firms stands at 821 as of Jan. 15, 1984, up from 728 on Dec. 15, 1983. The Index is composed of the 23 companies in the chart that are marked by an asterisk. For a more complete explanation of the Index, see BIO/TECHNOLOGY 1:536.

## McGILL DISPUTE

## CONTROVERSY ERUPTS OVER CANADIAN BIOTECH INVENTION

MONTREAL, Quebec—A fierce controversy over academic-industrial relations in biotechnology has exploded at McGill University, where two academic microbiologists have set up a commercial venture to exploit an invention they claim may be worth millions. Activities connected with the venture's launch have led to charges and countercharges involving possible misuse of the taxpayers' money, abuse of University facilities, unethical conduct, mishandling by academic authorities, stock market manipulation, and intimidation of students, as well as press censorship and contested patent rights.

Both the University and the two researchers involved insist no wrongdoing has taken place. In contrast to the U.S., where accusations of conflict of interest between the university and corporate sphere have not infrequently punctuated development of biotechnology, the McGill episode is one of the first in Canada. It is also

IMAGE  
UNAVAILABLE FOR  
COPYRIGHT  
REASONS

one of the most acrimonious to emerge anywhere.

The debates center around an invention developed by the chairman of McGill's department of microbiology and immunology, Irving DeVoe, and Bruce Holbein, an associate professor. The invention is a mechanism for cleaning up industrial wastes and nuclear contamination by taking toxic metals out of solution.

The researchers set up a company to exploit their discovery early in 1982, but the public controversy over the DeVoe-Holbein enterprise began only last October with an article in Montreal's daily paper, *The Gazette*, followed by a series of stories in a student paper, the *McGill Daily*, and derogatory pieces in Montreal's Sunday press. The papers credited present and former McGill students and staff, most of them anonymous, with a long list of accusations against the University and the researchers, including the misappropriation of